Balyasny Asset Management
CLVS

Balyasny Asset Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Balyasny Asset Management’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-400,000
Closed -$2.33M – 1816
2020
Q3 		$2.33M Buy
+400,000
New +$2.39M 0.02% 797
2019
Q1 		– Sell
-390,000
Closed -$7M – 1739
2018
Q4 		$7M Sell
390,000
-5,000
-1% -$102K 0.05% 436
2018
Q3 		$12.7M Buy
395,000
+237,500
+151% +$9.19M 0.06% 412
2018
Q2 		$7.16M Buy
157,500
+17,500
+13% +$851K 0.03% 580
2018
Q1 		$7.39M Buy
140,000
+15,000
+12% +$875K 0.03% 599
2017
Q4 		$8.5M Sell
125,000
-219,000
-64% -$15.3M 0.03% 687
2017
Q3 		$28.3M Buy
344,000
+179,000
+108% +$14.2M 0.11% 245
2017
Q2 		$15.4M Buy
165,000
+74,900
+83% +$4.58M 0.06% 395
2017
Q1 		$5.74M Sell
90,100
-359,900
-80% -$21.9M 0.03% 665
2016
Q4 		$20M Buy
+450,000
New +$15.8M 0.11% 275
2016
Q1 		– Sell
-50,000
Closed -$1.75M – 1597
2015
Q4 		$1.75M Buy
+50,000
New +$3.22M 0.01% 665

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Balyasny Asset Management's CLVS Position: Q3 2022 in Review

Balyasny Asset Management sold out of Clovis Oncology, Inc. (CLVS) in Q3 2022, closing a stake of 26,841 shares — an estimated $48K sold.

Balyasny Asset Management first reported a position in CLVS in Q2 2014 and held it in 21 quarters. The position peaked at $69.7M in Q1 2017. 103 funds tracked by Wall St. Rank hold CLVS as of Q3 2022.

  • Balyasny Asset Management reported no remaining Clovis Oncology, Inc. position as of Q3 2022 after selling out during the quarter.
  • Balyasny Asset Management sold 26,841 Clovis Oncology, Inc. shares in Q3 2022, an estimated $48K.
  • Balyasny Asset Management first reported a position in Clovis Oncology, Inc. in Q2 2014 and held it in 21 quarters.
  • Balyasny Asset Management's Clovis Oncology, Inc. position peaked at $69.7M in Q1 2017.
  • 103 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2022.

Based on Balyasny Asset Management's 13F filing for Q3 2022, filed 15 Nov 2022.